SCYNEXIS Reports $8.6 Million Net Loss in Q3 2025, Progresses Drug Development

SCYNEXIS, Inc. reported its financial results for the third quarter and the first nine months of 2025, revealing a net loss of $8.6 million for the quarter, compared to a loss of $2.8 million in the same period last year. For the nine months ended September 30, 2025, the company recorded a net loss of $20.9 million, an increase from a loss of $16.9 million in the prior year. License agreement revenue for the third quarter was $334,000, down 49.4% from $660,000 in the same quarter of 2024, and total revenue for the nine-month period decreased by 29.4% to $1.96 million from $2.77 million.

Operating expenses for the third quarter decreased by 20.4% to $8.7 million, primarily due to a significant reduction in research and development costs, which fell to $5.5 million from $8.1 million year-over-year. This decline was attributed to lower expenses in chemistry, manufacturing, and controls, as well as reduced clinical and preclinical costs. Conversely, selling, general, and administrative expenses increased by 13.1% to $3.3 million, driven by higher professional fees. The company’s total operating expenses for the nine months ended September 30, 2025, were $28.6 million, down from $31.8 million in the previous year.

In terms of strategic developments, SCYNEXIS has made significant progress in its drug development pipeline, particularly with its antifungal candidate SCY-247. The company recently completed the single and multiple ascending dose portions of a Phase 1 study for SCY-247, which demonstrated favorable safety and pharmacokinetics. The company plans to initiate a Phase 1 study of an intravenous formulation in early 2026 and anticipates a Phase 2 study for invasive candidiasis later that year. Additionally, SCYNEXIS entered into a binding memorandum of understanding with GlaxoSmithKline (GSK) to wind down the MARIO study, which will result in one-time payments totaling $24.8 million from GSK.

As of September 30, 2025, SCYNEXIS reported total assets of $51.1 million, a significant decrease from $90.6 million at the end of 2024. The company’s cash and cash equivalents stood at $14.8 million, down from $16.1 million at the end of the previous fiscal year. The accumulated deficit increased to $397.4 million. The company believes its current capital resources are sufficient to fund operations for at least the next 12 months, although it may require additional funding through equity offerings or other financing methods to support ongoing research and development activities.

Looking ahead, SCYNEXIS remains focused on advancing its antifungal therapies, particularly SCY-247, to address unmet medical needs in the treatment of invasive fungal infections. The company is also navigating challenges related to its stock price, having received a notification from Nasdaq regarding non-compliance with minimum bid price requirements. The management is optimistic about the potential for future collaborations and regulatory approvals that could enhance its financial position and market presence.